诱导TRIB2向蛋白质降解以逆转急性髓性白血病的化学抵抗
Evie Rigby1, Francesca Fasanella Masci1, Akshara Narayanan1
1Wolfson Wohl Translational Cancer Research Centre, School of Cancer Science, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
The Biochemical journal
|March 13, 2026
概括
通过促进TRIB2瘤基因的降解来向TRIB2瘤基因是治疗急性髓性白血病 (AML) 的有希望的策略. 这种方法提高了化疗的有效性,并克服了AML的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- TRIB2瘤基因通过抑制分化和促进化学抵抗,驱动急性髓性白血病 (AML).
- TRIB2在AML病变发生中的作用使其成为潜在的治疗点,但它仍未得到充分研究.
- 了解TRIB2降解对于开发新的AML治疗方法至关重要.
研究的目的:
- 在AML中全面研究TRIB2降解机制.
- 为了确定诱导TRIB2降解的小分子和策略.
- 在AML模型中评估TRIB2降解的治疗潜力.
主要方法:
- 在CRISPR的淘汰屏幕上.
- 突变蛋白稳定性测试试验
- 针对TRIB2参与的小分子选.
- 开发和评估一个TRIB2-PROTAC (组合5K)
- 在Ubiquitination网站绘制地图.
- 在体内进行白血病移植研究.
主要成果:
- 阿法替尼是一种ERBB抑制剂,迅速诱导TRIB2降解,导致AML细胞死亡.
- TRIB2 降解与细胞氨基酸协同作用,增强AML化疗的疗效.
- -63无处不在对于TRIB2的营业额至关重要;一种耐降解突变 (KallR) 增加了化学抵抗和移植.
- 对TRIB2的CRISPR淘汰证实了它在AML细胞存活中的重要作用.
- 一种新的TRIB2-PROTAC (化合物5K) 有效降解TRIB2并杀死AML细胞.
结论:
- TRIB2是AML的一个可行的治疗点.
- 通过ubiquitin-proteasome系统准TRIB2降解是克服化疗抵抗的一个有希望的策略.
- 这些发现为开发针对白血病的TRIB2向疗法提供了强有力的临床前基础.
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K


